Objective: To compare blood coagulation parameters between pregnant women with vaginal bleeding in the first trimester of pregnancy and pregnant women with normal pregnancy in the first trimester. Methods: A prospective controlled study of 98 women in the first trimester of vital pregnancy was conducted at the University Medical Centre Maribor, Slovenia. The study group comprised women with vaginal bleeding (n=50) while the control group women with normal pregnancy, admitted for artificial abortion (n=48). Prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen concentration, number of platelets, hemogram, coagulation factor VIII (FVIII) and von Willebrand factor (VWF) activity were compared between the 2 groups. Results: No significant between-group differences were detected in mean PT, fibrinogen concentration, FVIII, and VWF activity. Mean aPTT was significantly higher in the control group than the study group (32.47 versus 30.46 seconds; P(0.05). The mean number of platelets was significantly lower in the study group than the control group (181.69 versus 203.52x10 [on] 9/L; P(0.05). All measured coagulation parameters, except VWF activity, were within normal ranges. Conclusion: Coagulation abnormalities are rarely the cause of vaginal bleeding in the first trimester of pregnancy among women with no previous symptoms of bleeding disorders.
COBISS.SI-ID: 4373311
Namen: Namen raziskave je bil ugotoviti ali lahko na osnovi koncentracije estradiola (E2) in progesterona (P) ter njunega razmerja v folikularni tekočini predvidimo izhod IVF/ICSI postopkov v naravnih ciklusih. Metode: V raziskavo smo vključili 91 žensk, pri katerih smo naredili 150 postopkov IVF/ICSI (78 IVF in 72 ICSI) v naravnem ciklusu. Folikularno tekočino smo zbrali pri aspiraciji foliklov. S t-testom testom smo primerjali koncentracije E2 in P v folikularni tekočini (FT) in njuno razmerje (FT P/FT E2) med ciklusi z uspešno (z jajčno celico) in ciklusi z neuspešno (brez jajčne celice) aspiracijo foliklov, med ciklusi z oploditvijo in ciklusi brez oploditve jajčne celice in med ciklusi z zanositvijo in ciklusi brez zanositve. Rezultati: Jajčno celico smo dobili v 123 (86,7 %) ciklusih, do oploditve je prišlo v 84 (68,3 %) in zanositve v 21 ciklusih (delež zanositve na ciklus 14,0 %). Povprečna koncentracija E2 v FT je bila 3530 +/- 1339 nmol/L, povprečna koncentracija P v FT 20649 +/- 9489 nmol/L in povprečna vrednost razmerja FT P/FT E2 7,18 +/- 6,42. Povprečne vrednost E2, P in njunega razmerja v FT se niso statistično pomembno razlikovale med ciklusi z uspešno in neuspešno aspiracijo jajčnih foliklov, med ciklusi z in brez oploditve jajčne celice in med ciklusi z in brez zanositve. Zaključek: Na osnovi vrednosti E2 in P v folikularni tekočini ne moremo predvideti uspešnosti postopkov IVF/ICSI v naravnem ciklusu.
COBISS.SI-ID: 4331327
Overactive bladder (OAB) is a common, often debilitating, condition defined as urgency and urge incontinence, usually with frequency and nocturia. The use of muscarinic receptor antagonists are the mainstay of treatment, but their non-selectivity can result in unacceptable adverse effects that limit their usefulness. The purpose of this study was to evaluate 2 of the newer antimuscarinic agents, solifenacin and darifenacin, which demonstrate greater selectivity, in order to compare their tolerance and effectiveness. This was a multicentre, prospective, randomised, comparative (1:1) open-label study conducted in 4 centres comprising Slovenian gynaecologists and urologists. A total of 77 female patients with OAB were enrolled who received either solifenacin 5 mg or darifenacin 7.5 mg once daily. Study measurements consisted of changes in OAB symptoms and quality of life (QOL) evaluations after 1 and 3 months of treatment. Both treatment groups showing a reduction in all OAB symptoms but with no notable difference being seen between the 2 groups. Solifenacin though showed statistically greater improvements in QOL, better overall treatment satisfaction, and a decreased incidence of dry mouth after 3 months of treatment compared to the darifenacin group. This study demonstrates interesting initial results and indicates that these 2 drugs have a different profile that may confer an advantage to patients, but further methodologically rigorous studies comparing the use of solifenacin and darifenacin in OAB are required to establish the differences between these drugs over longer periods of treatment.
COBISS.SI-ID: 4567615
The aim of the randomised, double blind, placebo controlled study was to evaluate the efficacy, tolerability and safety of solifenacin, a once-daily M3 selective receptor antagonist, in patients with overactive bladder syndrome. Following a single blind 2-week placebo run in period, patients who complained from symptoms of OAB for at least 6 months, were randomized to 4 weeks of solifenacin in 5 mg once daily doses or placebo. 171 patients were enrolled in the study and 157 patients completed the study. Patients with solifenacin had significantly improved micturitions per 24 hours after first week of treatment (1.75 +/- 0.63 vs. 2.64 +/- 0.48, p(0.001), and after four weeks (1.56 +/- 0.58 vs. 2.71 +/- 0.45, p(0.001)compared to placebo group. The mean number of urgency episodes per 24 hours had significantly decreased in patients with solifenacin compared to placebo after first week (5.75 +/- 1.43 vs. 6.65 +/- 0.65, p(0.001), and after four weeks of treatment (5.77 +/- 1.33 vs. 6.54 +/- 0.50, p(0.001). Solifenacin was also significantly more effective than placebo in reducing the mean number of episodes of severe urgency from baseline to end point (5.83 +/- 1.16 vs. 6.48 +/- 0.50, p(0.001). Compared with changes obtained with placebo, episodes of urinary frequency were significanlty reduced after first week (0.3 vs. -0.5, p(0.001) and four weeks check up periods in patients treated with solifenacin (0.19 vs. -0.15, p(0.001). Episodes of nocturia was significantly reduced in patients treated with solifenacin after first week (0.3 vs. -0.5, p(0.001), and after four weeks treatment period (0.45 vs. -0.50, p(0.001). The number of incontinence episodes was also significantly decreased in solifenacin group compared to placebo group after first week (1.06 +/- 0.57 vs. 2.74 +/- 0.47, p(0.001) and four weeks check up (0.96 +/- 0.57 vs. 2.75 +/- 0.43, p(0.001). The most common adverse effects with solifenacin were drymouth and constipation. Adverse effects were mild or moderate severity. The discontinuation rate owing to adverse effects was 4.5%-6.7% with solifenacin and 3.8%-6.1% with placebo, respectively. According to subjective estimation, significant improvement was achieved in 71 (92.21%) of patients treated with solifenacin and in 68(85%) patients treated with placebo there was no change in OAB symptoms compared to baseline values. UDI score was significantly improved after solifenacin (22.26 +/- 5.91 vs. 29.61 +/- 8.45, p(0.001) compared to placebo. IIQ score was significantly decreased in patients with solifenacin (36.25 +/- 10.34 vs. 46.86 +/- 6.81, p(0.001) compared to placebo. In conclusion, solifenacin is a safe and effective treatment alternative for patients with overactive bladder symptoms.
COBISS.SI-ID: 4314175
Edini v državi izvajamo globoko možgansko stimulacijo. Operacijska nevromodulacija je reverzibilna uporaba električne stimulacije ali dovajanje farmakoloških snovi v osrednji živčni sistem z vgradnjo naprave v bolnikov telo. Namen je spreminjati aktivnost živčnega sistema (ekscitacija, inhibicija ali prilagajanje nevronov ali nevronske mreže) za zdravljenje specifičnih stanj. Globoka možganska stimulacija (GMS) je pomembna metoda za zdravljenje gibalnih motenj in je skoraj popolnoma nadomestila visokofrekvenčno koagulacijo možganovine. V članku predstavljamo prve slovenske primere GMS. Predstavili smo tehnične posebnosti in prilagoditve pri uporabi magnetne resonance ter razvoj novega mikrovodila, ki smo ga uspešno klinično preizkusili.
COBISS.SI-ID: 4294975